Nasdaq
$8.27▲ 1.53%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $577.2MShares out 69.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 9.30After-hours26.10.01 06:108-KKey event#●●●#●●●#●●●
Immix Biopharma, Inc.
Immix Biopharma has priced an underwritten offering of 11,363,637 shares of common stock at $11.00 per share, aiming to raise $125 million in gross proceeds. The company intends to use the net proceeds to fund the development of its lead candidate, NXC-201, and for general corporate purposes, with the offering expected to close on September 30, 2026.…more
$8.27+1.53%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29Pre-market26.09.29 20:25FWPOther
Immix Biopharma, Inc.
Immix Biopharma has priced an underwritten offering of 11,363,637 shares of common stock at $11.00 per share, aiming to raise $125 million in gross proceeds. The company intends to use the net proceeds to fund the development of its NXC-201 candidate and for general corporate purposes.…more
$8.27+1.53%vs prev closeView filingShare - 9.29Pre-market26.09.29 20:22424B5Offering
Immix Biopharma, Inc.
Immix Biopharma is conducting a public offering of 11,363,637 shares of common stock at a price of $11.00 per share, raising a total of $125,000,007. This offering will result in dilution for existing shareholders, and the proceeds will be used for clinical trials and general corporate purposes.…more
$8.27+1.53%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5Pre-market26.10.05 21:45#●●●#●●●
Immix Biopharma to Present at 45th J.P. Morgan Healthcare Conference
Immix Biopharma announced its participation in the upcoming 45th Annual J.P. Morgan Healthcare Conference in January 2027. This event is a standard industry presentation and does not provide immediate material impact on the company's financial outlook.…more
$8.27+1.53%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.30After-hours26.10.01 06:15
●●●●●●●● ●●●●● ●●●●●●
Immix Biopharma has completed a $125 million underwritten offering of its common stock. The company plans to use the net proceeds to fund the development of its NXC-201 candidate and for general corporate purposes.…more
$8.27+1.53%vs prev close - 9.29Pre-market26.09.29 20:00
●●●●●●●● ●●●●● ●●●●●●
Immix Biopharma announced an 89% complete response rate for its NXC-201 therapy in a Phase 2 clinical trial for AL amyloidosis. The company plans to submit a Biologics License Application (BLA) in mid-2027 based on these positive interim results.…more
$8.27+1.53%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report